Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1133843

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what guidance has been issued to clinical commissioning groups on restricting access to operations until a person's medical condition worsens; and if he will make a statement.
	tabling member constituency	Warrington North
	tabling member printed	Helen Jones
	uin	267717
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>It is for the local clinical commissioning group (CCG) to decide what services they commission for the people they are responsible for – this will mean making clinical judgements about the effectiveness and value of treatments, and the best allocation of resources. CCGs do this based on the healthcare needs of their local populations and clinical evidence, to ensure they are providing the best possible, sustainable care for their patients.</p><p> </p><p>Treatment decisions should always be made by doctors based on a patient’s individual clinical needs and informed by the National Institute for Health and Care Excellence’s (NICE) guidelines.</p><p> </p><p>NICE clinical guidelines make many recommendations spanning all stages of care from diagnosis to treatment of a condition. They represent best practice and are based on available evidence and developed through consultation. Health professionals and organisations are expected to take the guidance fully into account when deciding treatments.</p><p> </p><p>A fundamental principle of the National Health Service is that, for people who are ‘ordinarily resident’ in the United Kingdom, treatment is free at the point of need, regardless of the patient’s ability to pay. Patient payments, other than those limited forms permitted by Regulations (such as prescription charges, payments for some clinical activity undertaken by dentists, and visitor and migrant charges) are contrary to NHS policy.</p><p> </p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 267718 question first answered 26/06/2019 15:37:04 answering member 1585 label Biography information for Stephen Hammond
	tabling member	432 label Biography information for Helen Jones

1133844

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery: Private Sector
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what guidance has been issued to NHS Trusts on charging for operations which were previously offered free on the NHS.
	tabling member constituency	Warrington North
	tabling member printed	Helen Jones
	uin	267718
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>It is for the local clinical commissioning group (CCG) to decide what services they commission for the people they are responsible for – this will mean making clinical judgements about the effectiveness and value of treatments, and the best allocation of resources. CCGs do this based on the healthcare needs of their local populations and clinical evidence, to ensure they are providing the best possible, sustainable care for their patients.</p><p> </p><p>Treatment decisions should always be made by doctors based on a patient’s individual clinical needs and informed by the National Institute for Health and Care Excellence’s (NICE) guidelines.</p><p> </p><p>NICE clinical guidelines make many recommendations spanning all stages of care from diagnosis to treatment of a condition. They represent best practice and are based on available evidence and developed through consultation. Health professionals and organisations are expected to take the guidance fully into account when deciding treatments.</p><p> </p><p>A fundamental principle of the National Health Service is that, for people who are ‘ordinarily resident’ in the United Kingdom, treatment is free at the point of need, regardless of the patient’s ability to pay. Patient payments, other than those limited forms permitted by Regulations (such as prescription charges, payments for some clinical activity undertaken by dentists, and visitor and migrant charges) are contrary to NHS policy.</p><p> </p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 267717 question first answered 26/06/2019 15:37:04 answering member 1585 label Biography information for Stephen Hammond
	tabling member	432 label Biography information for Helen Jones

1133888

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the change in the level of the Public Health Grant on the (a) quality of drug treatment services and (b) number of drug-related deaths in the 2015 to 2019 Spending Review period .
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	267731
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Government is concerned by the number of drug-related deaths, which is largely caused by an ageing cohort of heroin users. We are supporting local areas to develop a more joined up approach to commissioning and delivering the range of services that are essential to supporting recovery and preventing drug-related deaths. In October, the Home Office announced that there would be a major independent review of drug misuse. This will look at a wide range of issues, including the system of support and enforcement around drug abuse, to better inform our thinking about what more can be done to tackle drug harms including deaths. The review shall inform our thinking about what more can be done to mitigate the harm caused through drug use.</p><p>Local authorities will receive £3.1 billion in 2019/20, ring-fenced exclusively for use on public health, including drug addiction. We are investing over £16 billion in local authority public health services over the five years of the 2015 Spending Review until 2020/21. Public health funding for 2020 onwards, including for addiction services, will be considered carefully in the next Spending Review, in the light of the available evidence.</p><p><strong> </strong></p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 267732 question first answered 26/06/2019 16:34:53 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3973 label Biography information for Grahame Morris

1133889

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the effect of the change to the level of the Public Health Grant over the forthcoming 2019 Spending Review on the (a) quality of drug treatment services and (b) number of drug-related deaths.
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	267732
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Government is concerned by the number of drug-related deaths, which is largely caused by an ageing cohort of heroin users. We are supporting local areas to develop a more joined up approach to commissioning and delivering the range of services that are essential to supporting recovery and preventing drug-related deaths. In October, the Home Office announced that there would be a major independent review of drug misuse. This will look at a wide range of issues, including the system of support and enforcement around drug abuse, to better inform our thinking about what more can be done to tackle drug harms including deaths. The review shall inform our thinking about what more can be done to mitigate the harm caused through drug use.</p><p>Local authorities will receive £3.1 billion in 2019/20, ring-fenced exclusively for use on public health, including drug addiction. We are investing over £16 billion in local authority public health services over the five years of the 2015 Spending Review until 2020/21. Public health funding for 2020 onwards, including for addiction services, will be considered carefully in the next Spending Review, in the light of the available evidence.</p><p><strong> </strong></p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 267731 question first answered 26/06/2019 16:34:53 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3973 label Biography information for Grahame Morris

1133890

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Death
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of preventable deaths caused by heart disease; and whether he has made an assessment of whether improving screening for older people would (a) help tackle the number of deaths attributed to heart disease and (b) be cost-effective.
	tabling member constituency	Ealing, Southall
	tabling member printed	Mr Virendra Sharma
	uin	267726
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Cardiovascular Disease (CVD) prevention initiatives report summarises a wide range of actions led by Public Health England (PHE) which will reduce preventable deaths from CVD. This can be viewed at the following link:</p><p><a href="http://www.healthcheck.nhs.uk/commissioners-and-providers/national-guidance/" target="_blank">www.healthcheck.nhs.uk/commissioners-and-providers/national-guidance/</a></p><p>In February 2018 PHE published national ambitions on the secondary prevention of Atrial Fibrillation, High Blood Pressure and High Cholesterol. This can be viewed at the following link:</p><p><a href="https://publichealthmatters.blog.gov.uk/2019/02/14/health-matters-preventing-cardiovascular-disease/" target="_blank">https://publichealthmatters.blog.gov.uk/2019/02/14/health-matters-preventing-cardiovascular-disease/</a></p><p>People aged 40-74 without existing disease are eligible once every five years for an NHS Health Check, England’s CVD prevention programme. Modelling shows that the programme, is cost effective with potential savings to the National Health Service of around £57 million per year after four years, rising to £176 million per year after 15 years. This equates to a cost per Quality Adjusted Life Year of around £3,000, considerably lower than the National Institute for Health and Care Excellence’s threshold. The cost benefits of the programme primarily arise from the opportunity it presents to prevent 1,600 heart attacks and strokes and save at least 650 lives each year. A copy of the Economic Modelling for Vascular Checks is attached.</p><p>The United Kingdom National Screening Committee has not undertaken an assessment of the impact of routine screening for the elderly to prevent deaths due to heart disease. Therefore, the Committee has not made a recommendation on this issue.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 267727 question first answered 26/06/2019 16:29:30 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Economic Modelling.pdf title Economic Modelling report
	tabling member	1604 label Biography information for Mr Virendra Sharma

1133891

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of heart disease screening programmes for the elderly on (a) the incidence of preventable disease and (b) NHS costs.
	tabling member constituency	Ealing, Southall
	tabling member printed	Mr Virendra Sharma
	uin	267727
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Cardiovascular Disease (CVD) prevention initiatives report summarises a wide range of actions led by Public Health England (PHE) which will reduce preventable deaths from CVD. This can be viewed at the following link:</p><p><a href="http://www.healthcheck.nhs.uk/commissioners-and-providers/national-guidance/" target="_blank">www.healthcheck.nhs.uk/commissioners-and-providers/national-guidance/</a></p><p>In February 2018 PHE published national ambitions on the secondary prevention of Atrial Fibrillation, High Blood Pressure and High Cholesterol. This can be viewed at the following link:</p><p><a href="https://publichealthmatters.blog.gov.uk/2019/02/14/health-matters-preventing-cardiovascular-disease/" target="_blank">https://publichealthmatters.blog.gov.uk/2019/02/14/health-matters-preventing-cardiovascular-disease/</a></p><p>People aged 40-74 without existing disease are eligible once every five years for an NHS Health Check, England’s CVD prevention programme. Modelling shows that the programme, is cost effective with potential savings to the National Health Service of around £57 million per year after four years, rising to £176 million per year after 15 years. This equates to a cost per Quality Adjusted Life Year of around £3,000, considerably lower than the National Institute for Health and Care Excellence’s threshold. The cost benefits of the programme primarily arise from the opportunity it presents to prevent 1,600 heart attacks and strokes and save at least 650 lives each year. A copy of the Economic Modelling for Vascular Checks is attached.</p><p>The United Kingdom National Screening Committee has not undertaken an assessment of the impact of routine screening for the elderly to prevent deaths due to heart disease. Therefore, the Committee has not made a recommendation on this issue.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 267726 question first answered 26/06/2019 16:29:30 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Economic Modelling.pdf title Economic Modelling report
	tabling member	1604 label Biography information for Mr Virendra Sharma

1133899

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many prescriptions for cannabis-based medicines have been (a) issued and (b) fulfilled since January 2018.
	tabling member constituency	Newport West
	tabling member printed	Ruth Jones
	uin	267788
	answer	answer is ministerial correction date of answer 01/07/2019 answer text <p>NHS England and NHS Improvement are using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England and NHS Improvement Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p>The NHS Business Services Authority is only able to provide information on prescriptions for cannabis-based medicines that have been prescribed and submitted to the NHS Business Services Authority. The NHS Business Services Authority does not hold information on prescriptions for cannabis-based medicines which have been issued but not fulfilled.</p><p>The following table shows the number of items for Nabilone and Sativex (licensed cannabis-based medicines) and unlicensed cannabis-based medicines that were prescribed on an NHS prescription, dispensed in the community and submitted to the NHS Business Services Authority for reimbursement between January 2018 and April 2019.</p><table><tbody><tr><td><p>NHS prescription items dispensed</p></td><td><p>January 2018 – April 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>752</p></td></tr><tr><td><p>Sativex</p></td><td><p>2,672</p></td></tr><tr><td><p>Unlicensed cannabis-based medicines</p></td><td><p>8 (data currently only available for November 2018 – March 2019). Data not yet available for April 2019.</p></td></tr></tbody></table><p> </p><p>The following table shows the same products listed above covering the same time period but this data relates to private prescribing on an FP10PCD where the forms have been submitted to the NHS Business Services Authority for reporting and monitoring purposes only.</p><table><tbody><tr><td><p>Private prescription items dispensed</p></td><td><p>January 2018 – December 2018</p></td><td><p>January 2019 – April 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>0</p></td><td><p>1</p></td></tr><tr><td><p>Sativex</p></td><td><p>24</p></td><td><p>13</p></td></tr><tr><td><p>Epidiolex</p></td><td><p>0</p></td><td><p>1</p></td></tr><tr><td><p>Unlicensed cannabis-based medicines</p></td><td><p>0</p></td><td><p>9 (data currently only available for January 2019 to March 2019). Data not yet available for April 2019.</p></td></tr></tbody></table><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p>Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that, up until the end of March 2019, five patients have had private prescriptions issued for a cannabis-based product for medicinal use in independent secondary/tertiary care in England.</p><p>145 patients have accessed Epidiolex though GW Pharma’s early access programmes ahead of a licensing decision by the European Medicines Agency.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 01/07/2019 15:34:02 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4716 label Biography information for Ruth Jones

1133914

	registered interest
	date	21/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Early Years Ministerial Group on Family Support
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the recommendations of the Inter Ministerial Group on early years family support have been agreed by his Department; and what further steps he has taken to improve early years family support.
	tabling member constituency	South Northamptonshire
	tabling member printed	Andrea Leadsom
	uin	267741
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Early Years Family Support Ministerial Group has been considering how the Government can improve the coordination and cost-effectiveness of early years (conception to age two) family support and identify gaps in available provision. The group has made recommendations to Secretaries of State which they are now considering.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 26/06/2019 16:22:21 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4117 label Biography information for Andrea Leadsom